The success rate from first-in-human to registration for neuroactive drugs targeting the CNS is significantly lower than for other indications, such as cardiovascular, infectious, inflammatory, and metabolic diseases 3,4
Start: 0.10 mL daily (200 mcg AOD / 100 mcg CJC / 100 mcg Ip)
Alma Skin, Pistactive Fusion (Italy) Italian biotech start-up Alma Skin introduced its patented Pistactive Fusion platform to the U.S
In addition, important pediatric-specific confounders, including age at diagnosis, duration of untreated disease, pubertal stage, growth velocity, baseline nutritional status, and family dietary environment, are inconsistently reported and may substantially influence metabolic trajectories